JP2024517335A - 組合せ治療方法 - Google Patents

組合せ治療方法 Download PDF

Info

Publication number
JP2024517335A
JP2024517335A JP2023570090A JP2023570090A JP2024517335A JP 2024517335 A JP2024517335 A JP 2024517335A JP 2023570090 A JP2023570090 A JP 2023570090A JP 2023570090 A JP2023570090 A JP 2023570090A JP 2024517335 A JP2024517335 A JP 2024517335A
Authority
JP
Japan
Prior art keywords
bupropion
nicotine
zonisamide
subject
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023570090A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517335A5 (https=
Inventor
ローズ，ジェド，イー．
Original Assignee
ローズ リサーチ センター，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ローズ リサーチ センター，エルエルシー filed Critical ローズ リサーチ センター，エルエルシー
Publication of JP2024517335A publication Critical patent/JP2024517335A/ja
Publication of JP2024517335A5 publication Critical patent/JP2024517335A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A24B15/167—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
    • A24B15/32—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances by acyclic compounds
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
    • A24F40/10—Devices using liquid inhalable precursors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2023570090A 2021-05-11 2022-05-10 組合せ治療方法 Pending JP2024517335A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163187001P 2021-05-11 2021-05-11
US63/187,001 2021-05-11
PCT/US2022/028504 WO2022240819A1 (en) 2021-05-11 2022-05-10 Combination treatment methods

Publications (2)

Publication Number Publication Date
JP2024517335A true JP2024517335A (ja) 2024-04-19
JP2024517335A5 JP2024517335A5 (https=) 2025-05-19

Family

ID=84028804

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023570090A Pending JP2024517335A (ja) 2021-05-11 2022-05-10 組合せ治療方法

Country Status (7)

Country Link
US (1) US20250073186A1 (https=)
EP (1) EP4337181A4 (https=)
JP (1) JP2024517335A (https=)
CN (1) CN117693335A (https=)
AU (1) AU2022273620A1 (https=)
CA (1) CA3218448A1 (https=)
WO (1) WO2022240819A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4593814A1 (en) * 2022-09-26 2025-08-06 Rose Research Center, LLC Combination for use in a method of preventing weight gain

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001518520A (ja) * 1997-10-03 2001-10-16 キャリー メディカル コーポレイション ニコチンレセプターアンタゴニストおよび抗抑うつ薬または抗不安薬を含有するニコチン嗜癖を治療する組成物
US20070212428A1 (en) * 2004-06-04 2007-09-13 Mood Management Sciences, Inc. Methods and compositions for treating mood disorder
US7671094B2 (en) * 2005-06-27 2010-03-02 Biovail Laboratories International S.R.L. Bupropion hydrobromide and therapeutic applications
KR20170077291A (ko) * 2006-11-09 2017-07-05 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지

Also Published As

Publication number Publication date
CN117693335A (zh) 2024-03-12
AU2022273620A1 (en) 2023-11-30
US20250073186A1 (en) 2025-03-06
EP4337181A4 (en) 2025-04-16
CA3218448A1 (en) 2022-11-17
EP4337181A1 (en) 2024-03-20
WO2022240819A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
Henningfield et al. Pharmacotherapy for Nicotine Dependence 1
Giulietti et al. Pharmacological Approach to Smoking Cessation: An Updated Review for Daily Clinical Practice: F. Giulietti et al.
Selby et al. Tobacco addiction
Tashkin Smoking cessation in chronic obstructive pulmonary disease
Aubin et al. Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice
Chapman et al. A randomised, open-label, cross-over clinical study to evaluate the pharmacokinetic, pharmacodynamic and safety and tolerability profiles of tobacco-free oral nicotine pouches relative to cigarettes
Casella et al. Therapeutic advances in the treatment of nicotine addiction: present and future
Rennard et al. Smoking cessation
Shiffman et al. Nicotine delivery systems
Aubin et al. Pharmacotherapy for smoking cessation: present and future
Glover et al. A multicenter phase 3 trial of lobeline sulfate for smoking cessation
JP2022548876A (ja) 嗜癖の治療および／または予防を必要とする対象の嗜癖の治療および／または予防におけるシチシンを含む組成物
Stack Smoking cessation: an overview of treatment options with a focus on varenicline
Frishman Smoking cessation pharmacotherapy
Schneider et al. Comparative testing of 5 nicotine systems: initial use and preferences
Bittoun A combination nicotine replacement therapy (NRT) algorithm for hard-to-treat smokers
JP2024517335A (ja) 組合せ治療方法
Talwar et al. Pharmacotherapy of tobacco dependence
Rosen et al. Reducing tobacco use in adolescents
Suchanek Hudmon et al. Current approaches to pharmacotherapy for smoking cessation
Agrawal et al. Medical management of inpatients with tobacco dependency
Grief Nicotine dependence: health consequences, smoking cessation therapies, and pharmacotherapy
de Hoyos et al. Perioperative smoking cessation
EP4593814A1 (en) Combination for use in a method of preventing weight gain
Crain et al. Current treatment options in smoking cessation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250509

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250509